 Cabaletta Bio, Inc. CABA, a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, and Artisan Bio, Inc., a precision cell therapy engineering company, today announced they have signed a research and collaboration agreement to accelerate development of next-generation CAAR T cell therapies for patients with B cell-mediated autoimmune diseases. This collaboration agreement with Artisan provides Cabaletta Labs with the potential to integrate this advanced gene editing and engineering technology into our next-generation CAAR T products as we continue to expand and enhance our CABA platform, said Gwendolyn Binder, Ph.D., EVP Science and Technology at Cabaletta Bio. 